MAPK1 and colorectal carcinoma: In addition, our findings of reactivation of the MEK/ERK pathway in the LY3009120-resistant cell line are in line with recent studies examining clinical acquired resistance of BRAFmut CRC to RAF inhibitor combinations due to genetic alterations in the MAPK pathway [9].